Abstract
“Neurodegenerative disease” is a term for a variety of disorders that primarily affect neurons in the human brain and spinal cord. These diseases are presently incurable and result in progressive degeneration or death of nerve cells, resulting in impaired movement (ataxia, Parkinsonism, paresis) or mental functions (dementia). The most common neurodegenerative diseases include Parkinson’s disease and other parkinsonian syndromes, Alzheimer’s disease and other non-Alzheimer’s dementias, Friedreich’s disease and other spinocerebellar atrophy, amyotrophic lateral sclerosis, and other diseases manifesting symptoms such as restriction of free movement, tremor, chorea, dystonia, myoclonus, other abnormal movements, dementia, and other cognitive disorders. Neurodegenerative diseases are highly prevalent and are among the most serious diseases in terms of health and socioeconomic impact. These diseases are not limited to older age groups, but affect also children and adults of working age. The current therapies cannot cure the diseases; they only ameliorate or relieve symptoms. All employed drugs have their targeted site of action in the central nervous system; thus, overcoming the blood–brain barrier is a necessity. Nanotechnology provides a new dimension and new properties to all materials and, in particular, allows central nervous system targeting of nanoscale formulations with increased brain permeation, and it is, thus, widely used for the production of a new generation of pharmaceuticals and theranostics with improved drug bioavailability, reduced undesirable side effects, minimized nonspecific uptake, and specific targeting to certain target cells. This chapter presents a comprehensive overview of recent findings in the field of investigation and application of nanoformulations tested/used for the alleviation or treatment of Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and Wilson’s disease as well as nanosensors applied for diagnostics or a treatment monitoring of neurodegenerative diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aalinkeel R, Kutscher HL, Singh A, Cwiklinski K, Khechen N, Schwartz SA, Prasad PN, Mahajan SD (2018) Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease? J Drug Target 26(2):182–193
Aghili Z, Nasirizadeh N, Divsalar A, Shoeibi S, Yaghmaei P (2018) A highly sensitive miR-195 nanobiosensor for early detection of Parkinson's disease. Artificial Cells, Nanomedicine, and Biotechnology 46(Supl 1):S32–S40
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A (2018) Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281: 139–177
Ahmad MZ, Ahmad J, Amin S, Rahman M, Anwar M, Mallick N, Ahmad FJ, Rahman Z, Kamal MA, Akhter S (2014) Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease. CNS Neurol Disord Drug Targets 13(8):1315–1324
Akbar M, Essa M, Daradkeh G, Abdelmegeed MA, Choi Y, Mahmood L, Songa BJ (2016) Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res 1637:34–55
Akhter S, Jain GK, Ahmad FJ, Khar RK, Jain N, Khan ZI, Talegaonkar S (2008) Investigation of nanoemulsion system for transdermal delivery of domperidone: ex-vivo and in vivo studies. Curr Nanosci 4(4):381–390
Alawdi SH, El-Denshary ES, Safar MM, Eidi H, David MO, Abdel-Wahhab MA (2017) Neuroprotective effect of nanodiamond in Alzheimer's disease rat model: a pivotal role for modulating NF-κB and STAT3 signaling. Mol Neurobiol 54(3):1906–1918
Al-Dhubiab BE (2013) Formulation and in vitro evaluation of gelatin nanospheres for the oral delivery of selegiline. Curr Nanosci 9(1):21–25
Ali SS, Hardt JI, Dugan LL (2008) SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study. Nanomedicine 4: 283–294
Ali T, Kim MJ, Rehman SU, Ahmad A, Kim MO (2017) Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in an Aβ1-42 mouse model of Alzheimer's disease. Mol Neurobiol 54(8):6490–6506
Aliakbari F, Mohammad-Beigi H, Rezaei-Ghaleh N, Becker S, Esmatabad D, Seyedi HAE, Bardania H, Marvian AT, Collingwood JF, Christiansen G, Zweckstetter M, Otzen DE, Mordhedi D (2018) The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's disease. Nanoscale 10(19):9174–9185
Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutova A, Baeesa SS, Avila-Rodriguez M, Ustyugov AA, Bachurin SO (2019) Alzheimer's disease - future therapy based on dendrimers. Curr Neuropharmacol 17(3):288–294
Aly AEE, Harmon BT, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL (2019) Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-hydroxydopamine model of Parkinson's disease. Mol Neurobiol 56(1):688–701
Alzheimer's Disease International (2015) World Alzheimer Report: The Global Impact of Dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf
Ambhore NS, Satyanarayana Raju KR, Mulukutla S, Yamjala K, Mohire S, Satyanarayana Reddy Karri VV, Gupta S, Murthy V, Elango K (2017) Brain targeting of 1,9-pyrazoloanthrone an c-Jun-N-terminal kinase inhibitor using liposomes for effective management of Parkinson's disease. Iran J Pharm Res 16(4):1463–1478
Andrade S, Ramalho MJ, Pereira MD, Loureiro JA (2018) Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol 9:1261
Andre EM, Passirani C, Seijo B, Sanchez A, Montero-Menei CN (2016) Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: application to Huntington's disease. Biomaterials 83:347–362
Ansari M, Habibi-Rezaei M, Salahshour-Kordestani S, Ferdousi M, Movahedi AAM (2016) An investigation on the effect of β-CD modified Fe3O4 magnetic nanoparticles on aggregation of amyloid-β peptide (25-35). Mater Technol 31(6):315–321
Antosova A, Bednarikova Z, Koneracka M, Antal I, Zavisova V, Kubovcikova M, Wu JW, Wang SSS, Gazova Z (2019) Destroying activity of glycine coated magnetic nanoparticles on lysozyme, α-lactalbumin, insulin and α-crystallin amyloid fibrils. J Magn Mater 471:169–176
Aoyagi A, Condello C, Stohr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Keene CD, Seeley WW, DeGrado WF, and Prusiner SB (2019) Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain. Sci Transl Med 11(490):8462
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503
Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N (2008) A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 58(3):287–297
Aso E, Martinsson I, Appelhans D, Effenberg C, Benseny-Cases N, Cladera J, Gouras G, Ferrer I, Klementieva O (2019) Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine 17:198–209
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D (2013) Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5:6
Attems J, Jellinger KA (2014) The overlap between vascular disease and Alzheimer's disease – lessons from pathology. BMC Med 12:206
Avachat AM, Oswal YM, Gujar KN, Shah RD (2014) Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles. Curr Drug Deliv 11(3):359–370
Azeem A, Ahmad FJ, Khar RK, Talegaonkar S (2009) Nanocarrier for the transdermal delivery of an antiparkinsonian drug. AAPS Pharm Sci Tech 10(4):1093–1103
Azeem A, Talegaonkar S, Negi LM, Ahmad FJ, Khar RK, Iqbal Z (2012) Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm 422(1–2):436–444
Aziz A, Asif M, Azeem M, Ashraf G, Wang ZY, Xiao F, Liu HF (2019) Self-stacking of exfoliated charged nanosheets of LDHs and graphene as biosensor with real-time tracking of dopamine from live cells. Anal Chim Acta 1047:197–207
Bajic V, Milovanovic ES, Spremo-Potparevic B, Zivkovic L, Milicevic Z, Stanimirovic J, Bogdanovic N, Isenovic ER (2016) Treatment of Alzheimer's disease: classical therapeutic approach. Curr Pharm Anal 12(2):82–90
Barnabas W (2019) Drug targeting strategies into the brain for treating neurological diseases. J Neurosci Methods 311:133–146
Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Investig 118:1532–1543
Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11:718–726
Baysal I, Yabanoglu-Ciftci S, Tunc-Sarisozen Y, Ulubayram K, Ucar G (2013) Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with β-amyloid fibrils. J Neural Transm 120(6):903–910
Begum AN, Aguilar JS, Elias L, Hong YL (2016) Silver nanoparticles exhibit coating and dose-dependent neurotoxicity in glutamatergic neurons derived from human embryonic stem cells. Neurotoxicology 57:45–53
Bello M, Junior AM, Vieira BA, Dias LRS, de Sousa VP, Castro HC, Rodrigues CR, Cabral LM (2015) Sodium montmorillonite/amine-containing drugs complexes: new insights on intercalated drugs arrangement into layered carrier material. PLoS One 10(3):e0121110
Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, Pohlmann AR, Guterres SS, Salbego CG (2012) Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine 7:4927–4942
Berry RW, Abraha A, Lagalwar S, LaPointe N, Gamblin TC, Cryns VL, Binder LI (2003) Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry 42:8325–8331
Bhak G, Lee S, Kim TH, Lee JH, Yang JE, Joo K, Lee J, Char K, Paik SR (2018) Morphological evaluation of meta-stable oligomers of α-synuclein with small-angle neutron scattering. Sci Rep 8:14295
Bhatt R, Singh D, Prakash A, Mishra N (2015) Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. Drug Deliv 22(7):931–939
Bhatt PC, Pathak S, Kumar V, Panda BP (2018) Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer's disease by fermented soybean nanonutraceutical. Inflammopharmacology 26(1):105–118
Bhavna MS, Ali M, Ali R, Bhatnagar A, Baboota S, Ali J (2014a) Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation. Int J Biol Macromol 67:418–425
Bhavna MS, Ali M, Bhatnagar A, Baboota S, Sahni JK, Ali J (2014b) Design, development, optimization and characterization of donepezil loaded chitosan nanoparticles for brain targeting to treat Alzheimer's disease. Sci Adv Mater 6(4):720–735
Bhavna MS, Ali M, Baboota S, Sahni JK, Bhatnagar A, Ali J (2014c) Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 40(2):278–287
Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739:216–223
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387–403
Bondi ML, Craparo EF, Giammona G, Drago F (2010) Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine 5:25–32
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson's disease: separating the wheat from the chaff. J Parkinsons Dis 7:S71–S85
Brahmkhatri VP, Sharma N, Sunanda P, D'Souza A, Raghothama S, Atreya HS (2018) Curcumin nanoconjugate inhibits aggregation of N-terminal region (Aβ-16) of an amyloid beta peptide. New J Chem 42(24):19881–19892
Brundin P, Li JY, Holton JL, Lindvall O, Revesz T (2008) Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 9:741–745
Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11:301–307
Burkhart A, Azizi M, Thomsen MS, Thomsen LB, Moos T (2014) Accessing targeted nanoparticles to the brain: the vascular route. Curr Med Chem 21(36):4092–4099
Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A (2016) Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv 13(8):1121–1131
Cannava C, Stancanelli R, Marabeti MR, Venuti V, Cascio C, Guarneri P, Bongiorno C, Sortino G, Majolino D, Mazzaglia A, Tommasini S, Ventura CA (2016) Nanospheres based on PLGA/amphiphilic cyclodextrin assemblies as potential enhancers of methylene blue neuroprotective effect. RSC Adv 6(20):16720–16729
Cao XB, Hou DZ, Wang L, Li S, Sun SG, Ping QN, Xu Y (2016) Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats. Biol Res 49:32
Carradori D, Balducci C, Re F, Brambilla D, Le Droumaguet B, Flores O, Gaudin A, Mura S, Forloni G, Ordonez-Gutierrez L, Wandosell F, Masserini M, Couvreur P, Nicolas J, Andrieux K (2018) Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine 14(2):609–618
Ceccon A, Tugarinov V, Clore GM (2019) TiO2 nanoparticles catalyze oxidation of huntingtin exon 1-derived peptides impeding aggregation: a quantitative NMR study of binding and kinetics. J Am Chem Soc 141(1):94–97
Chen ZL, Huang M, Wang XR, Fu J, Han M, Shen YQ, Xia Z, Gao JQ (2016) Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier. Nanomedicine 12(2):421–430
Chen LY, Watson C, Morsch M, Cole NJ, Chung RS, Saunders DN, Yerbury JJ, Vine KL (2017) Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles. Front Neurosci 11:476
Chieh JJ, Wei WC, Liao SH, Chen HH, Lee YF, Lin FC, Chiang MH, Chiu MJ, Horng HE, Yang SY (2018) Eight-channel AC magnetosusceptometer of magnetic nanoparticles for high-throughput and ultra-high-sensitivity immunoassay. Sensors 18(4):1043
Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9:124
Chiu MJ, Chen YF, Chen TF, Yang SY, Yang FPG, Tseng TW, Chieh JJ, Chen JCR, Tzen KY, Hua MS, Horng HE (2014) Plasma tau as a window to the brain negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 35(7):3132–3142
Choi I, Lee E, Lee LP (2013) Current nano/biotechnological approaches in amyotrophic lateral sclerosis. Biomed Eng Lett 3(4):209–222
Chung TH, Hsu SC, Wu SH, Hsiao JK, Lin CP, Yao M, Huang DM (2018) Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease. Nanoscale 10(6):2998–3007
Clark MS, Bond MJ, Hecker JR (2007) Environmental stress, psychological stress and allostatic load. Psychol Health Med 12:18–30
Clavaguera F, Hench J, Goedert M, Tolnay M (2015) Invited review: prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol 41:47–58
Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913
Clemens-Hemmelmann M, Kuffner C, Metz V, Kircher L, Schmitt U, Hiemke C, Postina R, Zentel R (2016) Amphiphilic copolymers shuttle drugs across the blood-brain barrier. Macromol Biosci 16(5):655–665
Collinge J (2016) Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 539:217–226
Corace G, Angeloni C, Malaguti M, Hrelia S, Stein PC, Brandl M, Gotti R, Luppi B (2014) Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 24(4):323–335
Coyle-Gilchrist IT, Dick KM, Patterson K, Vazquez Rodriquez P, Wehmann E, Wilcox A, Lansdall CJ, Dawson KE, Wiggins J, Mead S, Brayne C, Rowe JB (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86:1736–1743
Cui NN, Lu H, Li M (2018) Transferrin receptor antibodies for Alzheimer's disease. J Biomed Nanotechnol 14(5):1017–1024
Cummings J (2018) Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci 11:147–152
Debnath K, Pradhan N, Singh BK, Jana NR, Jana NR (2017) Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington's disease model mouse. ACS Appl Mater Interfaces 9(28):24126–24139
Demeritte T, Nellore BPV, Kanchanapally R, Sinha SS, Pramanik A, Chavva SR, Ray PC (2015) Hybrid graphene oxide based plasmonic-magnetic multifunctional nanoplatform for selective separation and label-free identification of Alzheimer's disease biomarkers. ACS Appl Mater Interfaces 7(24):13693–13700
Demirel M, Yazan Y, Muller RH, Kilic F, Bozan B (2001) Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 18(3):359–371
Di Stefano A, Iannitelli A, Laserra S, Sozio P (2011) Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 8(5):581–603
Do TD, Ul Amin F, Noh Y, Kim MO, Yoon J (2016) Guidance of magnetic nanocontainers for treating Alzheimer's disease using an elctromagnetic, targeted drug-delivery actuator. J Biomed Nanotechnol 12(3):569–574
Drug Bank (2019) Riluzole. https://www.drugbank.ca/drugs/DB00740
Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H (1990) Citicoline in the treatment of Parkinson's disease. Clin Ther 12(6):489–495
Elmizadeh H, Khanmohammadi M, Ghasemi K, Hassanzadeh G, Nassiri-Asl M, Garmarudi AB (2013) Preparation and optimization of chitosan nanoparticles and magnetic chitosan nanoparticles as delivery systems using box-Behnken statistical design. J Pharm Biomed Anal 80:141–146
Eslami M, Nikkhah SJ, Hashemianzadeh SM, Sajadi SAS (2016) The compatibility of memantine molecule with poly(n-butylcyanoacrylate) and chitosan as efficient carriers for drug delivery: a molecular dynamics study. Eur J Pharm Sci 82:79–85
Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, Cortesi R (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 25(7):1521–1530
Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, Drechsler M, Mazzoni S, Menegatti E, Morari M, Cortesi R (2012) Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm 80(2):306–314
Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, Goedert M (2018) Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 561:137–140
Fan LX, Wang JP, Meng FR, Luo Y, Sui X, Zhao BQ, Li WH, Quan DQ, Yang J, Wang YG (2018a) Delivering the acetylcholine neurotransmitter by nanodrugs as an effective treatment for Alzheimer's disease. J Biomed Nanotechnol 14(12):2066–2076
Fan SN, Zheng YQ, Liu X, Fang WL, Chen XY, Liao W, Jing XN, Lei M, Tao EX, Ma QL, Zhang XM, Guo R, Liu J (2018b) Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease. Drug Deliv 25(1):1044–1055
Fardanesh A, Zibaie S, Shariati B, Attar F, Rouhollah F, Akhtari K, Shahpasand K, Saboury AA, Falahati M (2019) Amorphous aggregation of tau in the presence of titanium dioxide nanoparticles: biophysical, computational, and cellular studies. Int J Nanomedicine 14:901–911
Fazil M, Md S, Hague S, Kumar M, Baboota S, Sahni JK, Ali J (2012a) Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47(1):6–15
Fazil M, Shadab BS, Sahni JK, Ali J (2012b) Nanotherapeutics for Alzheimer’s disease: past, present and future. J Drug Target 20(2):97–113
Fernandes C, Martins C, Fonseca A, Nunes R, Matos MJ, Silva R, Garrido J, Sarmento B, Remiao F, Otero-Espinar FJ, Uriarte E, Borges F (2018) PEGylated PLGA nanoparticles as a smart carrier to increase the cellular uptake of a coumarin-based monoamine oxidase B inhibitor. ACS Appl Mater Interfaces 10(46):39557–39569
Fernandez T, Martinez-Serrano A, Cusso L, Desco M, Ramos-Gomez M (2018) Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer's disease. ACS Chem Neurosci 9(5):912–924
Fernandez-Cabada T, Ramos-Gomez M (2019) A novel contrast agent based on magnetic nanoparticles for cholesterol detection as Alzheimer's disease biomarker. Nanoscale Res Lett 14:36
Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547:185–190
Fornaguera C, Feiner-Gracia N, Caldero G, Garcia-Celma MJ, Solans C (2015) Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7(28):12076–12084
Frost B, Ollesch J, Wille H, Diamond MI (2009) Conformational diversity of wild-type tau fibrils specified by templated conformation change. J Biol Chem 284:3546–3551
Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Matte A, Battastini AMO, Pohlmann AR, Guterres SS, Salbego C (2013a) Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol 47(3):1066–1080
Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Battastini AMO, Pohlmann AR, Guterres SS, Salbego C (2013b) Lipid-core nanocapsules improve the effects of resveratrol against Aβ-induced neuroinflammation. J Biomed Nanotechnol 9(12):2086–2104
Gabal YM, Kamel AO, Sammour OA, El Shafeey AH (2014) Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm 473(1–2):442–457
Gajofatto A, Benedetti MD (2015) Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases 3(7):545–555
Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 100:10032–10037
Gao N, Dong K, Zhao AD, Sun HJ, Wang Y, Ren JS, Qu XG (2016) Polyoxometalate-based nanozyme: design of a multifunctional enzyme for multi-faceted treatment of Alzheimer's disease. Nano Res 9(4):1079–1090
Gao GB, Chen R, He M, Li J, Li J, Wang LY, Sun TL (2019) Gold nanoclusters for Parkinson's disease treatment. Biomaterials 194:36–46
Ghalandari B, Asadollahi K, Shakerizadeh A, Komeili A, Riazi G, Kamrava SK, Attaran N (2019) Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy. J Photochem Photobiol B 192:131–140
Giau VV, An SSA, Hulme JP (2018) Mitochondrial therapeutic interventions in Alzheimer's disease. J Neurol Sci 395:62–70
Giglio V, Bellia F, Oliveri V, Vecchio G (2016) Aminocyclodextrin oligomers as protective agents of protein aggregation. Chem Plus Chem 81(7):660–665
Godinho BMDC, Ogier JR, Darcy R, Driscoll CM, Cryan JF (2013) Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol Pharm 10(2):640–649
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014
Gothwal A, Nakhate KT, Alexander A, Ajazuddin, Gupta U (2018) Boosted memory and improved brain bioavailability of rivastigmine: targeting effort to the brain using covalently tethered lower generation PAMAM dendrimers with lactoferrin. Mol Pharm 15(10):4538–4549
Goyal K, Koul V, Singh Y, Anand A (2014) Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances. Cent Nerv Syst Agents Med Chem 14(1):43–59
Grinberg LT, Heinsen H (2009) Argyrophilic grain disease: an update about a frequent cause of dementia. Dementia e Neuropsychologia 3:2–7
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913–4917
Gulati N, Nagaich U, Saraf S (2014) Fabrication and in vitro characterization of polymeric nanoparticles for Parkinson's therapy: a novel approach. Braz J Pharm Sci 50(4):869–876
Gumpelmayer M, Nguyen M, Molnar G, Bousseksou A, Meunier B, Robert A (2018) Magnetite Fe3O4 has no intrinsic peroxidase activity, and is probably not involved in Alzheimer's oxidative stress. Angew Chem Int Ed 57(45):14758–14763
Guo Q, You HH, Yang X, Lin BC, Zhu ZH, Lu ZS, Li XX, Zhao Y, Mao L, Shen SP, Cheng H, Zhang J, Deng L, Fan J, Xi Z, Li R, Li CM (2017a) Functional single-walled carbon nanotubes 'CAR' for targeting dopamine delivery into the brain of parkinsonian mice. Nanoscale 9(30):10832–10845
Guo JJ, Sun WQ, Liu FF (2017b) Brazilin inhibits the Zn2+-mediated aggregation of amyloid β-protein and alleviates cytotoxicity. J Inorg Biochem 177:183–189
Guo T, Noble W, Hanger DP (2017c) Roles of tau protein in health and disease. Acta Neuropathol 133(5):665–704
Hajimohammadjafartehrani M, Hosseinali SH, Dehkohneh A, Ghoraeian P, Ale-Ebrahim M, Akhtari K, Shahpasand K, Saboury AA, Attar F, Falahati M (2019) The effects of nickel oxide nanoparticles on tau protein and neuron-like cells: biothermodynamics and molecular studies. Int J Biol Macromol 127:330–339
Hajsalimi G, Taheri S, Shahi F, Attar F, Ahmadi H, Falahati M (2018) Interaction of iron nanoparticles with nervous system: an in vitro study. J Biomol Struct Dyn 36(4):928–937
Han QS, Wang XH, Liu XL, Zhang YF, Cai SF, Qi C, Wang C, Yang R (2019) MoO3-x nanodots with dual enzyme mimic activities as multifunctional modulators for amyloid assembly and neurotoxicity. J Colloid Interface Sci 539:575–584
Hanafy AS, Farid RM, El Gamal SS (2015) Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 41(12):2055–2068
Hao CL, Qu AH, Xu LG, Sun MZ, Zhang HY, Xu CL, Kuang H (2019) Chiral molecule-mediated porous CuxO nanoparticle clusters with antioxidation activity for ameliorating Parkinson's disease. J Am Chem Soc 141(2):1091–1099
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071
Hassani S, Laouini A, Fessi H, Charcosset C (2015) Preparation of chitosan-TPP nanoparticles using microengineered membranes - effect of parameters and encapsulation of tacrine. Colloids Surf A Physicochem Eng Asp 482:34–43
Hassanzadeh K, Nikzaban M, Moloudi MR, Izadpanah E (2015) Effect of selegiline on neural stem cells differentiation: a possible role for neurotrophic factors. Iran J Basic Med Sci 18(6):548–554
He ZZ, Elbaz A, Gao BB, Zhang JN, Su EB, Gu ZZ (2018) Disposable Morpho menelaus based flexible microfluidic and electronic sensor for the diagnosis of neurodegenerative disease. Adv Healthc Mater 7(5):1701306
Hegazy MA, Maklad HM, Abd Elmonsif DA, Elnozhy FY, Alqubiea MA, Alenezi FA, Al Abbas OM, Al Abbas MM (2017a) The possible role of cerium oxide (CeO2) nanoparticles in prevention of neurobehavioral and neurochemical changes in 6-hydroxydopamine-induced parkinsonian disease. Alexandria J Med 53(4):351–360
Hegazy MA, Maklad HM, Samy DM, Abdelmonsif DA, El Sabaa BM, Elnozahy FY (2017b) Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats. Neurochem Int 108:361–371
Hemmelmann M, Knoth C, Schmitt U, Allmeroth M, Moderegger D, Barz M, Koynov K, Hiemke C, Roesch F, Zentel R (2011) HPMA based amphiphilic copolymers mediate central nervous effects of domperidone. Macromol Rapid Commun 32(9–10):712–717
Hemmelmann M, Metz VV, Koynov K, Blank K, Postina R, Zentel R (2012) Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity. J Control Release 163(2):170–177
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14:388–405
Hernando S, Herran E, Figueiro-Silva J, Pedraz JL, Igartua M, Carro E, Hernandez RM (2018) Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson's disease. Mol Neurobiol 55(1):145–155
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J (2013) Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods. Alzheimers Dement 9:S4–S9
Hong S, Choi I, Lee S, Yang YI, Kang T, Yi J (2009) Sensitive and colorimetric detection of the structural evolution of superoxide dismutase with gold nanoparticles. Anal Chem 81:1378–1382
Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, Lightfoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ (2003) Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163:1021–1031
Hosseinali SH, Boushehri ZP, Rasti B, Mirpour M, Shahpasand K, Falahati M (2019) Biophysical, molecular dynamics and cellular studies on the interaction of nickel oxide nanoparticles with tau proteins and neuron-like cells. Int J Biol Macromol 125:778–784
Hsu SH, Wen CJ, Al-Suwayeh SA, Chang HW, Yen TC, Fang JY (2010) Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology 21(40):405101
Hsu SH, Al-Suwayeh SA, Chen CC, Chi CH, Fang JY (2011) PEGylated liposomes incorporated with nonionic surfactants as an apomorphine delivery system targeting the brain: in vitro release and in vivo real-time imaging. Curr Nanosci 7(2):191–199
Huang M, Hu M, Song QX, Song HH, Huang JL, Gu X, Wang XL, Chen J, Kang T, Feng XY, Jiang D, Zheng G, Chen H, Gao X (2015) GM1-modified lipoprotein-like nanoparticle: multifunctional nanoplatform for the combination therapy of Alzheimer's disease. ACS Nano 9(11):10801–10816
Huo XL, Zhang YQ, Jin XC, Li YG, Zhang L (2019) A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease. J Photochem Photobiol B 190:98–102
Hwang TL, Lin YK, Chi CH, Huang TH, Fang JY (2009) Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J Pharm Sci 98(10):3735–3747
Ianiski FR, Alves CB, Souza ACG, Pinton S, Roman SS, Rhoden CRB, Alves MP, Luchese C (2012) Protective effect of meloxicam-loaded nanocapsules against amyloid-β peptide-induced damage in mice. Behav Brain Res 230(1):100–107
Ianiski FR, Alves CB, Ferreira CF, Rech VC, Savegnago L, Wilhelm EA, Luchese C (2016) Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na+, K+-ATPase. Metab Brain Dis 31(4):793–802
Ikeda K, Okada T, Sawada S, Akiyoshi K, Matsuzaki K (2006) Inhibition of the formation of amyloid β-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett 580(28–29):6587–6595
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):656–664
Ishii T, Kawakami E, Endo K, Misawa H, Watabe K (2017) Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS One 12:e0179375
Ismail MF, El Meshad AN, Salem NAH (2013) Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int J Nanomedicine 8:393–406
Jafarieh O, Md S, Ali M, Baboota S, Sahni JK, Kumari B, Bhatnagar A, Ali J (2015) Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm 41(10):1674–1681
Jain NK, Rana AC, Jain SK (1998) Brain drug delivery system bearing dopamine hydrochloride for effective management of Parkinsonism. Drug Dev Ind Pharm 24(7):671–675
Jampílek J, Kráľová K (2015) Application of nanotechnology in agriculture and food industry, its prospects and risks. Ecological Chemistry and Engineering S 22(3):321–361
Jampílek J, Kráľová K (2017a) Nanopesticides: preparation, targeting and controlled release. In: Grumezescu AM (ed) Nanotechnology in the Agri-food industry, Vol. 10 – New pesticides and soil sensors. Elsevier, London, pp 81–127
Jampílek J, Kráľová K (2017b) Nano-antimicrobials: activity, benefits and weaknesses. In: Ficai A, Grumezescu AM (eds) Nanostructures in therapeutic medicine, Vol. 2 – Nanostructures for antimicrobial therapy. Elsevier, Amsterdam, pp 23–54
Jampílek J, Kráľová K (2017c) Nanomaterials for delivery of nutrients and growth-promoting compounds to plants. In: Prasad R, Kumar M, Kumar V (eds) Nanotechnology: An agricultural paradigm. Springer, Singapore, pp 177–226
Jampílek J, Kráľová K (2018a) Application of nanobioformulations for controlled release and targeted biodistribution of drugs. In: Sharma AK, Keservani RK, Kesharwani RK (eds) Nanobiomaterials: applications in drug delivery. CRC Press, Warentown, pp 131–208
Jampílek J, Kráľová K (2018b) Nanomaterials applicable in food protection. In: Rai RV, Bai JA (eds) Nanotechnology applications in the food industry. Taylor & Francis Group, Boca Raton, pp 75–96
Jampílek J, Kráľová K (2018c) Benefits and potential risks of nanotechnology applications in crop protection. In: Abd-Elsalam K, Prasad R (eds) Nanobiotechnology applications in plant protection. Springer, Cham, pp 189–246
Jampílek J, Kráľová K (2019a) Nanotechnology based formulations for drug targeting to central nervous system. In: Keservani RK, Sharma AK (eds) Nanoparticulate drug delivery systems. Apple Academic Press & CRC Press, Warentown, pp 151–220
Jampílek J, Kráľová K (2019b) Nano-biopesticides in agriculture: state of art and future opportunities. In: Koul O (ed) Nano-biopesticides today and future perspectives. Academic Press & Elsevier, Amsterdam, pp 397–447
Jampílek J, Kráľová K (2019c) Recent advances in lipid nanocarriers applicable in the fight against cancer. In: Grumezescu AM (ed) Nanoarchitectonics in biomedicine. Elsevier, Amsterdam, pp 219–294
Jampílek J and Kráľová K (2019d) Impact of nanoparticles on photosynthesizing organisms and their use in hybrid structures with some components of photosynthetic apparatus. In: Plant Nanobionics. Nanotechnology in the life sciences – Vol. 1– Advances in the understanding of nanomaterials research and applications. Prasad R (Ed.). Springer, pp. 255–332
Jampílek J, Kráľová K (2019e) Natural biopolymeric nanoformulations for brain drug delivery. In: Keservani RK, Sharma AK, Kesharwani RK (eds) Nanocarriers for brain targeting: Principles and applications. CRC Press, Warentown, pp 131–204
Jampílek J, Kos J, Kráľová K (2019) Potential of nanomaterial applications in dietary supplements and foods for special medical purposes. Nanomaterials 9(2):296
Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK (2012) Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine 8(2):250–260
Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK (2014) Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials 35(6):1967–1976
Jellinger KA, Attems J (2015) Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm 122:505–521
Jeon MSSG, Cha MY, Kim JI, Hwang TW, Kim KA, Kim TH, Song KC, Kim JJ, Moon M (2019) Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice. Nanomedicine 17:297–307
Jiang ZQ, Dong XY, Liu H, Wang YJ, Zhang L, Sun Y (2016) Multifunctionality of self-assembled nanogels of curcumin-hyaluronic acid conjugates on inhibiting amyloid β-protein fibrillation and cytotoxicity. React Funct Polym 104:22–29
Jiang ZQ, Dong XY, Yan X, Liu Y, Zhang L, Sun Y (2018) Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid β-protein aggregation and cytotoxicity. Sci Rep 8:3505
Jin GZ, Kim M, Shin US, Kim HW (2011) Neurite outgrowth of dorsal root ganglia neurons is enhanced on aligned nanofibrous biopolymer scaffold with carbon nanotube coating. Neurosci Lett 501:10–14
Joe VF, Kumar SS (2018) Formulation, characterization and determination of anti-Alzheimeric activity of tacrine loaded poly(lactide-co-glycolide) nanoparticles. Int J Pharm Sci Res 9(12):5111–5120
John T, Gladytz A, Kubeil C, Martin LL, Risselada HJ, Abel B (2018) Impact of nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles. Nanoscale 10(45):20894–20913
Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo JB, Siupka P, Schallburg-Nielsen M, Andresen TL, Moos T (2017) Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep 7:10396
Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, Dickson DW (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:137–153
Joshi SA, Chavhan SS, Sawant KK (2010) Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76(2):189–199
Joshi AS, Singh V, Gahane AY, Thakur AK (2019) Biodegradable nanoparticles containing mechanism based peptide inhibitors reduce polyglutamine aggregation in cell models and alleviate motor symptoms in Drosophila model of Huntington's disease. ACS Chem Neurosci 10(3):1603–1614
Kanazirska MV, Fuchs PM, Chen LP, Lal S, Verma J, Vassilev PM (2012) Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells. Curr Pharm Biotechnol 13(15):2761–2767
Kandanapitiye MS, Wang FJ, Valley B, Gunathilake C, Jaroniec M, Huang SD (2015a) Selective ion exchange governed by the Irving-Williams series in K2Zn3[Fe(CN)6]2 nanoparticles: toward a designer prodrug for Wilson's disease. Inorg Chem 54(4):1212–1214
Kandanapitiye MS, Gunathilake C, Jaroniec M, Huang SD (2015b) Biocompatible D-penicillamine conjugated Au nanoparticles: targeting intracellular free copper ions for detoxification. J Mater Chem B 3(27):5553–5559
Kang YJ, Cutler EG, Cho HS (2018) Therapeutic nanoplatforms and delivery strategies for neurological disorders. Nano Convergence 5:35
Karaboga MNS, Sezginturk MK (2019) Cerebrospinal fluid levels of alpha-synuclein measured using a poly-glutamic acid-modified gold nanoparticle-doped disposable neuro-biosensor system. Analyst 144(2):611–621
Karavasili C, Bouropoulos N, Sygellou L, Amanatiadou EP, Vizirianakis IS, Fatouros DG (2016) PLGA/DPPC/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment. Mater Sci Eng C Mater Biol Appl 59:1053–1062
Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK (2018) Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease. Drug Deliv 25(1):307–320
Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI (2016) Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92:796–812
Kaushik AC, Bharadwaj S, Kumar S, Wei DQ (2018) Nano-particle mediated inhibition of Parkinson's disease using computational biology approach. Sci Rep 8:9169
Kermani ZR, Haghighi SS, Hajihosseinali S, Fashami AZ, Akbaritouch T, Akhtari K, Shahpasand K, Falahati M (2018) Aluminium oxide nanoparticles induce structural changes in tau and cytotoxicity of the neuroblastoma cell line. Int J Biol Macromol 120(Pt a):1140–1148
Kheradmand E, Moghaddam AH, Zare M (2018) Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer's disease. Biomed Pharmacother 97:1096–1101
Kim H, Lee JU, Song S, Kim S, Sim SJ (2018) A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers. Biosens Bioelectron 101:96–102
Kovacech B, Novák M (2010) Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr Alzheimer Res 7:708–716
Kovacech B, Skrabana R, Novák M (2010) Transition of tau protein from disordered to misordered in Alzheimer's disease. Neurodegener Dis 7:24–27
Kozik V, Bąk A, Pentak D, Hachuła B, Pytlakowska K, Rojkiewicz M, Jampílek J, Sieroń K, Jazowiecka-Rakus J, Sochanik A (2019) Derivatives of graphene oxide as potential drug carriers. J Nanosci Nanotechnol 19(5):2489–2492
Kulikova OI, Berezhnoy DS, Stvolinsky SL, Lopachev AV, Orlova VS, Fedorova TN (2018) Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. Regul Toxicol Pharmacol 95:254–259
Kumar S, Dang S, Nigam K, Ali J, Baboota S (2018a) Selegiline nanoformulation in attenuation of oxidative stress and upregulation of dopamine in the brain for the treatment of Parkinson's disease. Rejuvenation Res 21(5):464–476
Kumar P, Choonara YE, du Toit LC, Singh N, Pillay V (2018b) In vitro and in silico analyses of nicotine release from a gelisphere-loaded compressed polymeric matrix for potential Parkinson's disease interventions. Pharmaceutics 10(4):233
Kumar J, Erana H, Lopez-Martinez E, Claes N, Martin VF, Solis DM, Bals S, Cortajarena AL, Castilla J, Liz-Marzan LM (2018c) Detection of amyloid fibrils in Parkinson's disease using plasmonic chirality. Proc Natl Acad Sci USA 115(13):3225–3230
Kunasekaran V, Krishnamoorthy K (2015) Experimental design for the optimization of nanoscale solid lipid particles containing rasagiline mesylate. J Young Pharm 7(4):285–295
Kuo YC, Rajesh R (2018) Current development of nanocarrier delivery systems for Parkinson's disease pharmacotherapy. J Taiwan Inst Chem Eng 87:15–25
Kuo YC, Tsai HC (2018) Rosmarinic acid- and curcumin-loaded polyacrylamide-cardiolipin-poly (lactide-co-glycolide) nanoparticles with conjugated 83-14 monoclonal antibody to protect β-amyloid-insulted neurons. Mater Sci Eng C Mater Biol Appl 91:445–457
Kuo YC, Tsao CW (2017) Neuroprotection against apoptosis of SK-N-MC cells using RMP-7-and lactoferrin-grafted liposomes carrying quercetin. Int J Nanomedicine 12:2857–2869
Kuo YC, Lin CY, Li JS, Lou YI (2017) Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer's disease treatment. Int J Nanomedicine 12:1757–1774
Kuo YC, Chen IY, Rajesh R (2018) Use of functionalized liposomes loaded with antioxidants to permeate the blood-brain barrier and inhibit β-amyloid-induced neurodegeneration in the brain. J Taiwan Inst Chem Eng 87:1–14
Kura AU, Hussein-Al-Ali SH, Hussein MZ, Fakurazi S, Arulselvan P (2013) Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine 8:1103–1110
Kura AU, Hussein-Al-Ali SH, Hussein MZ, Fakurazi S (2014a) Preparation of tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system. Sci World J 2014:104246
Kura AU, Hussein-Al-Ali SH, Hussein MZ, Fakurazi S, Hussein-Al-Ali SH (2014b) Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model. Int J Mol Sci 15(4):5916–5927
Kwon HJ, Kim D, Seo K, Kim YG, Han SI, Kang T, Soh M, Hyeon T (2018) Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson's disease. Angew Chem Int Ed 57(30):9408–9412
Laserra S, Basit A, Sozio P, Marinelli L, Fornasari E, Cacciatore I, Ciulla M, Turkez H, Geyikoglu F, Di Stefano A (2015) Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization. Int J Pharm 485(1–2):183–191
Lauzon MA, Marcos B, Faucheux N (2018) Characterization of alginate/chitosan-based nanoparticles and mathematical modeling of their SpBMP-9 release inducing neuronal differentiation of human SH-SY5Y cells. Carbohydr Polym 181:801–811
Lazar AN, Mourtas S, Youssef I, Parizot C, Dauphin A, Delatour B, Antimisiaris SG, Duyckaerts C (2013) Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine 9(5):712–721
Ledesma MD, Bonay P, Colaco C, Avila J (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269:21614–21619
Lee BI, Chung YJ, Par CB (2019) Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's β-amyloid self-assembly. Biomaterials 190:121–132
Legendre JY, Rault I, Petit A, Luijten W, Demuynck I, Horvath S, Ginot YM, Cuine A (1995) Effects of β-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur J Pharm Sci 3(6):311–322
Lehtonen JYA, Rytomaa M, Kinnunen PKJ (1996) Characteristics of the binding of tacrine to acidic phospholipids. Biophys J 70(5):2185–2194
Li WZ, Zhou YQ, Zhao N, Hao BH, Wang XN, Kong P (2012) Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 34(2):272–279
Li C, Lu JY, Hu XL, Feng C, Xiang Y, Karamanos Y, Li GX (2018a) Assembly of nanoconjugates as new kind inhibitor of the aggregation of amyloid peptides associated with Alzheimer's disease. Part Part Syst Charact 35(3):1700384
Li X, Xie BL, Dong XY, Sun Y (2018b) Bifunctionality of iminodiacetic acid-modified lysozyme on inhibiting Zn2+-mediated amyloid β-protein aggregation. Langmuir 34(17):5106–5115
Li X, Xie BL, Sun Y (2018c) Basified human lysozyme: a potent inhibitor against amyloid β-protein fibrillogenesis. Langmuir 34(50):15569–15577
Li XY, Liu QQ, Zhu DH, Che YZ, Feng XZ (2019a) Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice. Biomater Sci 7:1623–1631
Li B, Zhang R, Shi XH (2019b) Aggregation of amyloid peptides into fibrils driven by nanoparticles and their curvature effect. Phys Chem Chem Phys 21(4):1784–1790
Liao A (2011) Citicoline sodium liposome solid preparation useful for protecting brain and neurons, and preventing and/or treating diseases, comprises citicoline sodium, phospholipid, additive and auxiliary materials. CN patent no. 102,078.299 A
Liu W, Ma S, Zhang X, Hua J, Yan L, Zhou F (2009) Rotigotine flexible liposome as pharmaceuticals, contains solid components including rotigotine, phospholipids and surface activating agent, and solvents including ether, chloroform, ethanol, aqueous ethanol solution or water. CN patent no. 101,317,819 A
Liu G, Men P, Perry G, Smith MA (2010) Nanoparticle and iron chelators as a potential novel Alzheimer therapy. In: Uppu RM, Murthy SN, Pryor WA, Parinandi NL (eds) Free radicals and antioxidant protocols, 2nd edn. Springer & Humana Press, New York, pp 123–144
Liu KS, Sung KC, Al-Suwayeh SA, Ku MC, Chu CC, Wang JJ, Fang JY (2011a) Enhancement of transdermal apomorphine delivery with a diester prodrug strategy. Eur J Pharm Biopharm 78(3):422–431
Liu JJ, Wang CY, Wang JG, Ruan HJ, Fan CY (2011b) Peripheral nerve regeneration using composite poly(lactic acid-caprolactone)/nerve growth factor conduits prepared by coaxial electrospinning. J Biomed Mater Res A 96:13–20
Liu KS, Wen CJ, Yen TC, Sung KC, Ku MC, Wang JJ, Fang JY (2012) Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting. Nanotechnology 23(9):095103
Liu ZY, Gao XL, Kang T, Jiang MY, Miao DY, Gu GZ, Hu QY, Song QX, Yao L, Tu YF, Chen HZ, Jiang XG, Chen J (2013a) B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug Chem 24(6):997–1007
Liu ZY, Jiang MY, Kang T, Miao DY, Gu GZ, Song QX, Yao L, Hu QY, Tu YF, Pang ZQ, Chen H, Jiang X, Gao X, Chen J (2013b) Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 34(15):3870–3881
Liu FF, Wang WJ, Sang JC, Jia LG, Lu FP (2019) Hydroxylated single-walled carbon nanotubes inhibit Aβ42 fibrillogenesis, disaggregate mature fibrils, and protect against Aβ42-induced cytotoxicity. ACS Chem Neurosci 10(1):588–598
Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E (2017) Covalent nanodelivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev 113:177–200
Lopalco A, Cutrignelli A, Denora N, Lopedota A, Franco M, Laquintana V (2018) Transferrin functionalized liposomes loading dopamine HCl: development and permeability studies across an in vitro model of human blood-brain barrier. Nano 8(3):178
Lopez T, Ortiz E, Meza D, Basaldella E, Bokhimi X, Magana C, Sepulveda A, Rodriguez F, Ruiz J (2011) Controlled release of phenytoin for epilepsy treatment from titania and silica based materials. Mater Chem Phys 126(3):922–929
Lotfabadi A, Hajipour MJ, Derakhshankhah H, Peirovi A, Saffar S, Shams E, Fatemi E, Barzegari E, Sarvari S, Moakedi F, Ferdousi M, Atyabi F, Saboury AA, Dinarvand R (2018) Biomolecular corona dictates Aβ fibrillation process. ACS Chem Neurosci 9(7):1725–1734
Loureiro JA, Gomes B, Fricker G, Coelho MAN, Rocha S, Pereira MC (2016) Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. Colloids Surf B: Biointerfaces 145:8–13
Lucas MJ, Keitz BK (2018) Influence of zeolites on amyloid-β aggregation. Langmuir 34(33):9789–9797
Luo Q, Lin YX, Yang PP, Wang Y, Qi GB, Qiao ZY, Li BN, Zhang K, Zhang JP, Wang L, Wang H (2018) A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat Commun 9:1802
Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, Catenacci L, Di Pietra AM, Zecchi V (2011) Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44(4):559–565
Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian DA, Yaffe K (2006) Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 14:561–572
Ma MM, Gao N, Sun YH, Du XB, Ren JS, Qu XG (2018) Redox-activated near-infrared-responsive polyoxometalates used for photothermal treatment of Alzheimer's disease. Adv Healthc Mater 7(20):1800320
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4
Majerova P, Garruto RM, Kovac A (2018) Cerebrovascular inflammation is associated with tau pathology in Guam parkinsonism dementia. J Neural Transm 125:1013–1025
Mancini S, Minniti S, Gregori M, Sancini G, Cagnotto A, Couraud PO, Ordonez-Gutierrez L, Wandosell F, Salmona M, Re F (2016) The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease. Nanomedicine 12(1):43–52
Mandal M, Mukherjee A, Gupta S (2018) New vista in Parkinson's disease treatment: magic of nanotechnology. J Indian Chem Soc 95(8):997–1002
Mao ZL, Xu B, Ji XL, Zhou K, Zhang XM, Chen MJ, Han XM, Tang QS, Wang XR, Xia YK (2015) Titanium dioxide nanoparticles alter cellular morphology via disturbing the microtubule dynamics. Nanoscale 7(18):8466–8475
Masserini M (2013) Nanoparticles for brain drug delivery. ISRN Biochemistry 2013:238428
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer's disease. Nat Rev Dis Primers 1:15056
Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One 7(3):e32616
Mathew G, Dey P, Das R, Chowdhury SD, Das MP, Veluswamy P, Neppolian B, Das J (2018) Direct electrochemical reduction of hematite decorated graphene oxide (α-Fe2O3@erGO) nanocomposite for selective detection of Parkinson's disease biomarker. Biosens Bioelectron 115:53–60
Mazibuko Z, Choonara YE, Kumar P, Du Toit LC, Modi G, Naidoo D, Pillay V (2015) A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. J Pharm Sci 104(4):1213–1229
McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC (2013) The spectrum of disease in chronic traumatic encephalopathy. Brain 136:43–64
Md S, Kumar M, Baboota S, Sahni JK, Ali J (2012) Preparation, characterization and evaluation of bromocriptine loaded chitosan nanoparticles for intranasal delivery. Sci Adv Mater 4(9):949–960
Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, Ali J (2013) Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 48(3):393–405
Md S, Haque S, Fazil M, Kumar M, Baboota S, Sahni JK, Ali J (2014) Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 11(6):827–842
Md S, Bhattmisra SK, Zeeshan F, Shahzad N, Mujtaba MA, Meka VS, Radhakrishnan A, Kesharwani P, Baboota S, Ali J (2018) Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. J Drug Deliv Sci Technol 43:295–310
Mehdizadeh P, Fesharaki SSH, Nouri M, Ale-Ebrahim M, Akhtari K, Shahpasand K, Saboury AA, Falahati M (2019) Tau folding and cytotoxicity of neuroblastoma cells in the presence of manganese oxide nanoparticles: biophysical, molecular dynamics, cellular, and molecular studies. Int J Biol Macromol 125:674–682
Mehta D, Jackson R, Paul G, Ji S, Sabbagh M (2017) Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs 26(6):735–739
Meng FF, Asghar S, Gao SY, Su ZG, Song J, Huo MR, Meng WD, Ping QN, Xiao YY (2015) A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. Colloids Surf B: Biointerfaces 134:88–97
Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012) Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 11(1):40–49
Milani MDM (2013) Citicoline as coadiuvant treatment of cognitive impairment in chronic degenerative central nervous system diseases and in ischemic stroke: a review of available data. Online J Med Med Sci Res 2(2):13–18
Miri AL, Hosni AP, Gomes JC, Mainardes RM, Khalil NM, Del JV, Marcano RG, da Silva Pereira MC, Kerppers II (2019) Study of the effects of L-tryptophane nanoparticles on motor behavior in Alzheimer's experimental models. CNS Neurol Disord Drug Targets 18(1):44–51
Mishra AD, Patel CN, Shah DR (2013) Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride. Curr Drug Deliv 10(5):500–516
Misra AR, Ghandi NI, Bajaj MR, Shah BB, Samant RS, Jamil ASP (2010) Liposomal citicoline injection WO 2010092597:A2
Misra S, Chopra K, Sinha VR, Medhi B (2016) Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 23(4):1434–1443
Mittal D, Md S, Hasan Q, Fazil M, Ali A, Baboota S, Ali J (2016) Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 23(1):130–139
Mittapelly N, Rachumallu R, Pandey G, Sharma S, Arya A, Bhatta RS, Mishra PR (2016) Investigation of salt formation between memantine and pamoic acid: its exploitation in nanocrystalline form as long acting injection. Eur J Pharm Biopharm 101:62–71
Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB (2007) Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 13:746–757
Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235:1641–1644
Mudedla SK, Murugan NA, Agren H (2018) Free energy landscape for alpha-helix to beta-sheet interconversion in small amyloid forming peptide under nanoconfinement. J Phys Chem B 122(42):9654–9664
Mudedla SK, Murugan NA, Subramanian V, Agren H (2019) Destabilization of amyloid fibrils on interaction with MoS2-based nanomaterials. RSC Adv 9(3):1613–1624
Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, van Vuuren S, Ndesendo VMK, du Toit LC, Iyuke SE, Pillay V (2013) Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm 448(1):267–281
Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W (2016) Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci 92:224–234
Muronetz V, Asryants R, Semenyuk P, Schmalhausen E, Saso L (2014) Hydrophobic plant antioxidants. Preparation of nanoparticles and their application for prevention of neurodegenerative diseases. Review and experimental data. Curr Top Med Chem 14(22):2520–2528
Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR, Dickson DW (2015) Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain 138(Pt 5):1370–1381
Mustafa G, Baboota S, Ali J, Kumar N, Singh T, Bhatnagar A, Ahuja A (2012a) Effect of homogenization on the fate of true nanoemulsion in brain translocation: a gamma scintigraphic evaluation. Sci Adv Mater 4(7):739–748
Mustafa G, Baboota S, Ahuja A, Ali J (2012b) Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of Parkinson: An in vitro ex vivo evaluation. Curr Nanosci 8(3):348–360
Mustafa G, Ahuja A, Al Rohaimi AH, Muslim S, Hassan AA, Baboota S, Ali J (2015) Nano-ropinirole for the management of parkinsonism: blood-brain pharmacokinetics and carrier localization. Expert Rev Neurother 15(6):695–710
Nagy ZK, Nyul K, Wagner I, Molnar K, Marosi G (2010) Electrospun water soluble polymer mat for ultrafast release of donepezil HCl. Express Polym Lett 4(12):763–772
Nair KGS, Ramaiyan V, Sukumaran SK (2018) Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis. Inflammopharmacology 26(3):675–684
Nasr SH, Kouyoumdjian H, Mallett C, Ramadan S, Zhu DC, Shapiro EM, Huang XF (2018) Detection of β-amyloid by sialic acid coated bovine serum albumin magnetic nanoparticles in a mouse model of Alzheimer's disease. Small 14(3):1701828
Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, Sonnen JA, Poon LW, Gearing M, Green RC, Woodard JL, Van Eldik LJ, Kryscio RJ (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134:1506–1518
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381
Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White ICL, Yu L, Schneider JA (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503–1527
Ngwuluka NC, Choonara YE, Kumar P, du Toit LC, Modi G, Pillay V (2015) An optimized gastroretentive nanosystem for the delivery of levodopa. Int J Pharm 494(1):49–65
Nicholas J, Wiley AB, Madhankumar RM, Mitchell EB, Neely ER, Gregory L, Douds ZS, James RC (2012) Lipopolysaccharide modified liposomes for amyotropic lateral sclerosis therapy: efficacy in SOD1 mouse model. Advances in Nanoparticles 1(3):44–53
Nouri M, Esfahanizadeh N, Shahpar MG, Attar F, Sartipnia N, Akhtari K, Saboury AA, Falahati M (2018) Cobalt oxide nanoparticles mediate tau denaturation and cytotoxicity against PC-12 cell line. Int J Biol Macromol 118.(Pt B:1763–1772
Novák M (1994) Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol 38:173–189
Novák M, Wischik CM, Edwards P, Pannell R, Milstein C (1989) Characterisation of the first monoclonal antibody against the pronase resistant core of the Alzheimer PHF. Prog Clin Biol Res 317:755–761
Novák M, Jakes R, Edwards PC, Milstein C, Wischik CM (1991) Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci USA 88:5837–5841
Novák M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12:365–370
Novák P, Prcina M, Kontsekova E (2011) Tauons and prions: infamous cousins? J Alzheimers Dis 26:413–430
Novák P, Kontsekova E, Zilka N, Novák M (2018a) Ten years of tau-targeted immunotherapy: the path walked and the roads ahead. Front Neurosci 12:798
Novák P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Zilka N, Winblad B, Novák M (2018b) FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther 10:108
Nunes A, Al-Jamal KT, Kostarelos K (2012) Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J Control Release 161(2):290–306
Oh J, Lee JS, Jun J, Kim SG, Jang J (2017) Ultrasensitive and selective organic FET-type nonenzymatic dopamine sensor based on platinum nanoparticles-decorated reduced graphene oxide. ACS Appl Mater Interfaces 9(45):39526–39533
Ojha S, Kumar B (2018) A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis. Journal of Cellular Immunotherapy 4(2):56–64
Ozkizilcik A, Sharma A, Muresanu DF, Lafuente JV, Tian ZR, Patnaik R, Moessler H, Sharma HS (2018a) Timed release of cerebrolysin using drug-loaded titanate nanospheres reduces brain pathology and improves behavioral functions in Parkinson's disease. Mol Neurobiol 55(1):359–369
Ozkizilcik A, Williams R, Tian ZR, Muresanu DF, Sharma A, Sharma HS (2018b) Synthesis of biocompatible titanate nanofibers for effective delivery of neuroprotective agents. Methods in Molecular Biology – Neurotrophic Factors 1727:433–442
Pagar KP, Sardar SM, Vavia PR (2014) Novel l-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease. J Biomed Nanotechnol 10(3):415–426
Pahuja R, Seth K, Shukla A, Shukla RK, Bhatnagar P, Chauhan LKS, Saxena PN, Arun J, Chaudhari BP, Patel DK, Singh SP, Shukla R, Khanna VK, Kumar P, Chaturvedi RK, Gupta KC (2015) Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 9(5):4850–4871
Paka GD, Doggui S, Zaghmi A, Safar R, Dao L, Reisch A, Klymchenko A, Roullin VG, Joubert O, Ramassamy C (2016) Neuronal uptake and neuroprotective properties of curcumin-loaded nanoparticles on SK-N-SH cell line: role of poly(lactide-co-glycolide) polymeric matrix composition. Mol Pharm 13(2):391–403
Palle S, Neerati P (2018) Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease. Naunyn Schmiedeberg's Arch Pharmacol 391(4):445–453
Pandey PK, Sharma AK, Rani S, Mishra G, Kandasamy G, Patra AK, Rana M, Sharma AK, Yadav AK, Gupta U (2018) MCM-41 nanoparticles for brain delivery: better choline-esterase and amyloid formation inhibition with improved kinetics. ACS Biomater Sci Eng 4(8):2860–2869
Pansieri J, Gerstenmayer M, Lux F, Meriaux S, Tillement O, Forge V, Larrat B, Marquette C (2018) Magnetic nanoparticles applications for amyloidosis study and detection: a review. Nano 8(9):740
Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol 15:73–88
Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M (2008) Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym 73(1):44–54
Parikh A, Kathawala K, Li JT, Chen C, Shan ZN, Cao X, Wang YJ, Garg S, Zhou XF (2018) Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model. Drug Des Devel Ther 12:2111–2128
Park JK, Bin Choy Y, Oh JM, Kim JY, Hwang SJ, Choy JH (2008) Controlled release of donepezil intercalated in smectite clays. Int J Pharm 359(1–2):198–204
Park DJ, Choi JH, Lee WJ, Um SH, Oh BK (2017) Selective electrochemical detection of dopamine using reduced graphene oxide sheets-gold nanoparticles modified electrode. J Nanosci Nanotechnol 17(11):8012–8018
Parthipan AK, Gupta N, Pandey K, Sharma B, Jacob J, Saha S (2019) One-step fabrication of bicompartmental microparticles as a dual drug delivery system for Parkinson's disease management. J Mater Sci 54(1):730–744
Patel P, Pol A, More S, Kalaria DR, Kalia YN, Patravale VB (2014) Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation. J Biomed Nanotechnol 10(11):3291–3303
Pentak D, Kozik V, Bąk A, Dybał P, Sochanik A, Jampílek J (2016) Methotrexate and cytarabine – loaded nanocarriers for multidrug cancer therapy. Spectroscopic study. Molecules 21(12):1689
Perera VS, Liu HJ, Wang ZQ, Huang SPD (2013) Cell-permeable Au@ZnMoS4 core-shell nanoparticles: toward a novel cellular copper detoxifying drug for Wilson's disease. Chem Mater 25(23):4703–4709
Pisárčik M, Jampílek J, Devínsky F, Drábiková J, Tkacz J, Opravil T (2016) Gemini surfactants with polymethylene spacer: Supramolecular structures at solid surface and aggregation in aqueous solution. J Surfactant Deterg 19(3):477–486
Pisárčik M, Jampílek J, Lukáč M, Horáková R, Devínsky F, Bukovský M, Kalina M, Tkacz J, Opravil T (2017) Silver nanoparticles stabilised by cationic gemini surfactants with variable spacer length. Molecules 22(10):1794
Pisárčik M, Lukáč M, Jampílek J, Bilka F, Bilková A, Pašková Ľ, Devínsky F, Horáková R, Opravil T (2018) Silver nanoparticles stabilised with cationic single-chain surfactants. Structure-physical properties-biological activity relationship study. J Mol Liq 272:60–72
Plissonneau M, Pansieri J, Heinrich-Balard L, Morfin JF, Stransky-Heilkron N, Rivory P, Mowat P, Dumoulin M, Cohen R, Allémann É, Tόth É, Saraiva MJ, Louis C, Tillement O, Forge V, Lux F, Marquette C (2016) Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting. J Nanobiotechnol 14(1):60
Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, Selva J, Egea G, Lopez-Iglesias C, Teixido M, Kogan MJ, Giralt E (2012) Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33(29):7194–7205
Prasad RS, Yandrapu SK, Manavalan R (2010) Lipid solid dispersions for the aqueous solubility and bioavailability enhancement of entacapone. Asian J Chem 22:4549–4558
Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95:13363–13383
Rahmani S, Mogharizadeh L, Attar F, Rezayat SM, Mousavi SE, Falahati M (2018) Probing the interaction of silver nanoparticles with tau protein and neuroblastoma cell line as nervous system models. J Biomol Struct Dyn 36(15):4057–4071
Raj R, Wairkar S, Sridhar V, Gaud R (2018) Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol 109:27–35
Rajput AP, Butani SB (2018) Nose to brain delivery of donepezil. Asian J Pharm 12(4):293–302
Rajput A, Bariya A, Allam A, Othman S, Butani SB (2018) In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization. Drug Deliv Transl Res 8(5):1460–1470
Rakotoarisoa M, Angelova A (2018) Amphiphilic nanocarrier systems for curcumin delivery in neurodegenerative disorders. Medicines 5(4):126
Ramachandran S, Thangarajan S (2016) A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington's disease-like symptoms in Wistar rats. Chem Biol Interact 256:25–36
Ramachandran S, Thangarajan S (2018) Thymoquinone loaded solid lipid nanoparticles counteracts 3-nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease. Metab Brain Dis 33(5):1459–1470
Rao SV, Meherunnisa M, Padmalatha K (2018) Formulation, characterisation and in vitro evaluation of novel ionically cross linked casein nanoparticles for memantine hydrochloride delivery. Int J Pharm Sci Res 9(8):3307–3316
Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R (2015) Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Mater Sci Eng C Mater Biol Appl 48:294–300
Ray S, Sinha P, Laha B, Maiti S, Bhattacharyya UK, Nayak AK (2018) Polysorbate 80 coated crosslinked chitosan nanoparticles of ropinirole hydrochloride for brain targeting. J Drug Deliv Sci Technol 48:21–29
Reddy JS, Venkateswarlu V, Koning GA (2006) Radioprotective effect of transferrin targeted citicoline liposomes. J Drug Target 14(1):13–19
Requejo C, Ruiz-Ortega JA, Cepeda H, Sharma A, Sharma HS, Ozkizilcik A, Tian R, Moessler H, Ugedo L, Lafuente JV (2018) Neuroprotective effects in a preclinical rat model of Parkinson's disease. Mol Neurobiol 55(1):286–299
Respondek G, Hoglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Supl.1):S34–S36
Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Investig 114:121–130
Roshanfekmahzomi Z, Badpa P, Esfandiari B, Taheri S, Nouri M, Akhtari K, Shahpasand K, Falahati M (2019) Silica nanoparticles induce conformational changes of tau protein and oxidative stress and apoptosis in neuroblastoma cell line. Int J Biol Macromol 124:1312–1320
Ross AM, Rahmani S, Prieskorn DM, Dishman AF, Miller JM, Lahann J, Altschuler RA (2016) Persistence, distribution, and impact of distinctly segmented microparticles on cochlear health following in vivo infusion. J Biomed Mater Res A 104(6):1510–1522
Ross C, Taylor M, Fullwood N, Allsop D (2018) Liposome delivery systems for the treatment of Alzheimer's disease. Int J Nanomedicine 13:8507–8522
Rukmangathen R, Yallamalli IM, Yalavarthi PR (2018) Biopharmaceutical potential of selegiline loaded chitosan nanoparticles in the management of Parkinson's disease. Curr Drug Discov Technol,. in press. https://doi.org/10.2174/1570163815666180418144019
Ruozi B, Belletti D, Pederzoli F, Veratti P, Forni F, Vandelli MA, Tosi G (2014) Nanotechnology and Alzheimer's disease: what has been done and what to do. Curr Med Chem 21(36):4169–4185
Ruozi B, Belletti D, Sharma HS, Sharma A, Muresanu DF, Moessler H, Forni F, Vandelli MA, Tosi G (2015) PLGA nanoparticles loaded cerebrolysin: studies on their preparation and investigation of the effect of storage and serum stability with reference to traumatic brain injury. Mol Neurobiol 52(2):899–912
Rzigalinski BA, Carfagna CS, Ehrich M (2017) Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(4):e1444
Sadowska-Bartosz I, Bartosz G (2018) Redox nanoparticles: synthesis, properties and perspectives of use for treatment of neurodegenerative diseases. J Nanobiotechnol 16:87
Sanati AL, Faridbod F, Ganjali MR (2017) Synergic effect of graphene quantum dots and room temperature ionic liquid for the fabrication of highly sensitive voltammetric sensor for levodopa determination in the presence of serotonin. J Mol Liq 241:316–320
Sanchez-Lopez E, Ettcheto M, Egea MA, Espina M, Cano A, Cristina CA, Camins A, Carmona N, Silva AM, Souto EB, Garcia ML (2018) Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. J Nanobiotechnol 16:32
Sancini G, Dal Magro R, Ornaghi F, Balducci C, Forloni G, Gobbi M, Salmona M, Re F (2016) Pulmonary administration of functionalized nanoparticles significantly reduces β-amyloid in the brain of an Alzheimer's disease murine model. Nano Res 9(7):2190–2201
Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S (2014) Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. NeuroMolecular Med 16(1):106–118
Sangubotla R, Kim J (2018) Recent trends in analytical approaches for detecting neurotransmitters in Alzheimer's disease. Trends Anal Chem 105:240–250
Sardjono RE, Khoerunnisa F, Musthopa I, Akasum NSMM, Rachmawati R (2018) Synthesize, characterization, and anti-Parkinson activity of silver-Indonesian velvet beans (Mucuna pruriens) seed extract nanoparticles (AgMPn). J Phys Conf Ser 1013:012195
Satheesh MNV (2014) Carbidopa bio-nanoparticles for brain targeting via ear. IN Patent 201203451 I1
Sathya S, Shanmuganathan B, Manirathinam G, Ruckmani K, Devi KP (2018a) α-Bisabolol loaded solid lipid nanoparticles attenuates Aβ aggregation and protects Neuro2a cells from Aβ induced neurotoxicity. J Mol Liq 264:431–441
Sathya S, Shanmuganathan B, Saranya S, Vaidevi S, Ruckmani K, Devi KP (2018b) Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer's toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function. Artif Cells Nanomed Biotechnol 46(8):1719–1730
Schlich M, Longhena F, Faustini G, O'Driscoll CM, Sinico C, Fadda AM, Bellucci A, Lai F (2017) Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: evaluation of alpha-synuclein knockdown efficacy. Nano Res 10(10):3496–3508
Schulz JB, Hausmann L, Hardy J (2016) 199 years of Parkinson disease - what have we learned and what is the path to the future. J Neurochem 139(Suppl. 1):3–7
Scialabba C, Rocco F, Licciardi M, Pitarresi G, Ceruti M, Giammona G (2012) Amphiphilic polyaspartamide copolymer-based micelles for rivastigmine delivery to neuronal cells. Drug Deliv 19(6):307–316
Sevcik J, Skrabana R, Dvorsky R, Csokova N, Iqbal K, Novák M (2007) X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease. FEBS Lett 581:5872–5878
Shah B, Khunt D, Bhatt H, Misra M, Padh H (2015) Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 78:54–66
Shan L, Tao EX, Meng QH, Hou WX, Liu K, Shang HC, Tang JB, Zhang WF (2016) Formulation, optimization, and pharmacodynamic evaluation of chitosan/phospholipid/β-cyclodextrin microspheres. Drug Des Devel Ther 10:417–429
Shao XR, Ma WJ, Xie XP, Li QS, Lin SY, Zhang T, Lin YF (2018) Neuroprotective effect of tetrahedral DNA nanostructures in a cell model of Alzheimer's disease. ACS Appl Mater Interfaces 10(28):23682–23692
Shariati B, Yektadoost E, Behzadi E, Azmoodeh E, Attar F, Sari S, Akhtari K, Falahati M (2018) Interaction of silica nanoparticles with tau proteins and PC12 cells: colloidal stability, thermodynamic, docking, and cellular studies. Int J Biol Macromol 118(Pt B):1963–1973
Sharma S, Lohan S, Murthy RSR (2014) Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 40(7):869–878
Shi YB, Liu QY, Yuan W, Xue M, Feng W, Li FY (2019) Dye-assembled upconversion nanocomposite for luminescence ratiometric in vivo bioimaging of copper ions. ACS Appl Mater Interfaces 11(1):430–436
Shin JW, Kim KJ, Yoon J, Jo J, El-Said WA, Choi JW (2017) Silver nanoparticle modified electrode covered by graphene oxide for the enhanced electrochemical detection of dopamine. Sensors 17(12):2771
Shui BQ, Tao D, Florea A, Cheng J, Zhao Q, Gu YY, Li W, Jaffrezic-Renault N, Mei Y, Guo ZZ (2018a) Biosensors for Alzheimer's disease biomarker detection: a review. Biochemie 147:13–24
Shui BQ, Tao D, Cheng J, Mei Y, Jaffrezic-Renault N, Guo ZZ (2018b) A novel electrochemical aptamer-antibody sandwich assay for the detection of tau-381 in human serum. Analyst 143(15):3549–3554
Siddiqi KS, Husen A, Sohrab SS, Yassin MO (2018) Recent status of nanomaterial fabrication and their potential applications in neurological disease management. Nanoscale Res Lett 13:231
Siddique YH, Khan W, Fatima A, Jyoti S, Khanam S, Naz F, Rahul AF, Singh BR, Naqvi AH (2016) Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease. Dis Model Mech 9(1):63–68
Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, De Deyn PP, Santens P, Van Broeckhoven C, Cruts M (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 124:353–372
Silva AC, Gonzalez-Mira E, Lobo JMS, Amaral MH (2013) Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia. Curr Pharm Des 19(41):7185–7195
Simko M, Mattson MO (2014) Interactions between nanonized materials and the brain. Curr Med Chem 21(37):4200–4214
Singh AV, Khare M, Gade WN, Zamboni P (2012) Theranostic implications of nanotechnology in multiple sclerosis: a future perspective. Autoimmune Diseases 2012:160830
Singh D, Rashid M, Hallan SS, Mehra NK, Prakash A, Mishra N (2016) Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif Cells Nanomed Biotechnol 44(3):865–877
Singh NA, Bhardwaj V, Ravi C, Ramesh N, Mandal AKA, Khan ZA (2018a) EGCG nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of Alzheimer's disease. Front Aging Neurosci 10:244
Singh NA, Mandal AKA, Khan ZA (2018b) Inhibition of Al(III)-induced Aβ42 fibrillation and reduction of neurotoxicity by epigallocatechin-3-gallate nanoparticles. J Biomed Nanotechnol 14(6):1147–1158
Singh V, Deepak RNVK, Sengupta B, Joshi AS, Fan H, Sen P, Thakur AK (2018c) Calmidazolium chloride and its complex with serum albumin prevent huntingtin exon1 aggregation. Mol Pharm 15(8):3356–3368
Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD (2010) Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J Pharm 389(1–2):207–212
Somani S, Robb G, Pickard BS, Dufes C (2015) Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex. J Control Release 217:235–242
Song MH, Sun YX, Luo Y, Zhu YY, Liu YS, Li HY (2018) Exploring the mechanism of inhibition of Au nanoparticles on the aggregation of amyloid-β(16-22) peptides at the atom level by all-atom molecular dynamics. Int J Mol Sci 19(6):1815
Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134:187–205
Sridhar V, Gaud R, Bajaj A, Wairkar S (2018) Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease. Nanomedicine 14(8):2609–2618
Stefanova N, Wenning GK (2016) Review: Multiple system atrophy: emerging targets for interventional therapies. Neuropathol Appl Neurobiol 42:20–32
Streit WJ, Xue QS (2014) Human CNS immune senescence and neurodegeneration. Curr Opin Immunol 29:93–96
Streit WJ, Braak H, Xue QS, Bechmann I (2009) Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118:475–485
Subczynski WK, Wojas J, Pezeshk V, Pezeshk A (1998) Partitioning and localization of spin-labeled amantadine in lipid bilayers: An EPR study. J Pharm Sci 87(10):1249–1254
Suganthy N, Ramkumar VS, Pugazhendhi A, Benelli G, Archunan G (2018) Biogenic synthesis of gold nanoparticles from Terminalia arjuna bark extract: assessment of safety aspects and neuroprotective potential via antioxidant, anticholinesterase, and antiamyloidogenic effects. Environ Sci Pollut Res 25(11):10418–10433
Sun M, Gao Y, Guo CY, Cao FL, Song ZM, Xi YW, Yu AH, Li AG, Zhai GX (2010) Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res 12(8):3111–3122
Sun C, Ding Y, Zhou L, Shi D, Sun L, Webster TJ, Shen Y (2017) Noninvasive nanoparticle strategies for brain tumor targeting. Nanomedicine 13(8):2605–2621
Sun J, Xie WJ, Zhu XF, Xu MM, Liu J (2018) Sulfur nanoparticles with novel morphologies coupled with brain-targeting peptides RVG as a new type of inhibitor against metal-induced Aβ aggregation. ACS Chem Neurosci 9(4):749–761
Sunena SSK, Mishra DN (2019) Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv 16(1):51–58
Tan JM, Foo JB, Fakurazi S, Hussein MZ (2015) Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol 6:243–253
Thatipamula RP, Palem CR, Gannu R, Mudragada S, Yamsani MR (2011) Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. DARU J Pharm Sci 19(1):23–32
Thongrangsalit S, Phaechamud T, Lipipun V, Ritthidej GC (2015) Bromocriptine tablet of self-microemulsifying system adsorbed onto porous carrier to stimulate lipoproteins secretion for brain cellular uptake. Colloids Surf B Biointerfaces 131:162–169
Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P, Karmakar M, Kumari M, Chauhan LKS, Patel DK, Srivastava V, Singh D, Gupta SK, Tripathu A, Chaturvedi RK, Gupta KC (2014) Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway. ACS Nano 8(1):76–103
Tomasovicova N, Hu PS, Zeng CL, Majorosova J, Zakutanska K, Kopcansky P (2018) Dual size-dependent effect of Fe3O4 magnetic nanoparticles upon interaction with lysozyme amyloid fibrils: disintegration and adsorption. Nano 9(1):37
Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ (2019) Micro- and nanotechnology approaches to improve Parkinson's disease therapy. J Control Release 295:201–213
Trapani A, Mandracchia D, Tripodo G, Cometa S, Cellamare S, De Giglio E, Klepetsanis P, Antimisiaris SG (2018) Protection of dopamine towards autoxidation reaction by encapsulation into non-coated- or chitosan- or thiolated chitosan-coated-liposomes. Colloids Surf B Biointerfaces 170:11–19
Tremmel R, Uhl P, Helm F, Wupperfeld D, Sauter M, Mier W, Stremmel W, Hofhaus G, Fricker G (2016) Delivery of copper-chelating trientine (TETA) to the central nervous system by surface modified liposomes. Int J Pharm 512(1):87–95
Truran S, Weissig V, Madine J, Davies HA, Guzman-Villanueva D, Franco DA, Karamanova N, Burciu C, Serrano G, Beach TG, Migrino RQ (2016) Nanoliposomes protect against human arteriole endothelial dysfunction induced by β-amyloid peptide. J Cereb Blood Flow Metab 36(2):405–412
Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, Tsai YH (2011) Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100(2):547–557
Tsai MJ, Fu YS, Lin YH, Huang YB, Wu PC (2014) The effect of nanoemulsion as a carrier of hydrophilic compound for transdermal delivery. PLoS One 9(7):e102850
Tucholski J, Kuret J, Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73:1871–1880
Tzeyung AS, Md S, Bhattamisra SK, Madheswaran T, Alhakamy NA, Aldawsari HM, Radhakrishnan AK (2019) Fabrication, optimization, and evaluation of rotigotine-loaded chitosan nanoparticles for nose-to-brain delivery. Pharmaceutics 11(1):26
Ul Amin F, Hoshiar AK, Do TD, Noh Y, Shah SA, Khan MS, Yoon J, Kim MO (2017) Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. Nanoscale 9(30):10619–10632
Vaculíková E, Černíková A, Plachá D, Pisárčik M, Dedková K, Peikertová P, Devínský F, Jampílek J (2016a) Cimetidine nanoparticles for permeability enhancement. J Nanosci Nanotechnol 16(8):7840–7843
Vaculíková E, Černíková A, Plachá D, Pisárčik M, Peikertová P, Dedková K, Devínský F, Jampílek J (2016b) Preparation of hydrochlorothiazide nanoparticles for solubility enhancement. Molecules 21(8):1005
Vaculíková E, Pokorná A, Plachá D, Pisárčik M, Dedková K, Peikertová P, Devínský F, Jampílek J (2019) Improvement of glibenclamide water solubility by nanoparticle preparation. J Nanosci Nanotechnol 19(5):3031–3034
Vakilinezhad MA, Amini A, Javar HA, Zarandi BFBB, Montaseri H, Dinarvand R (2018) Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer's disease animal model by reducing tau hyperphosphorylation. DARU J Pharm Sci 26(2):165–177
Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Bardile CF, Leoni V, Caccia C, Brilli E, Di Donato S, Boido MM, Vercelli A, Vandelli MA, Forni F, Cepeda C, Levine MS, Tosi G, Cattaneo E (2015) Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. EMBO Mol Med 7(12):1547–1564
Vargas-Osorio Z, Da Silva-Candal A, Piñeiro Y, Iglesias-Rey R, Sobrino T, Campos F, Castillo J, Rivas J (2019) Multifunctional superparamagnetic stiff nanoreservoirs for blood brain barrier applications. Nano 9(3):449
Vassiliou AA, Papadimitriou SA, Bikiaris DN, Mattheolabakis G, Avgoustakis K (2010) Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers. J Control Release 148(3):388–395
Vilaca-Faria H, Salgado AJ, Teixeira FG (2019) Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson's disease? Cell 8(2):E118
Vilella A, Belletti D, Sauer AK, Hagmeyer S, Sarowar T, Masoni M, Stasiak N, Mulvihill JJE, Ruozi B, Forni F, Vandelli MA, Tosi G, Zoli M, Grabrucker AM (2018) Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J Trace Elem Med Biol 49:210–221
Wahba SMR, Darwish AS, Kamal SM (2016) Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer's disease in ovariectomized albino-rat model. Mater Sci Eng C Mater Biol Appl 65:151–163
Walker FO (2007) Huntington's disease. Lancet 369:218–228
Wang P, Wang ZY (2017) Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease. Ageing Res Rev 35:265–290
Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Glycosylation of microtubule-associated protein tau: An abnormal posttranslational modification in Alzheimer's disease. Nat Med 2:871–875
Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX (2015) Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies. Int J Nanomedicine 10:633–644
Wang ML, Li L, Zhang XW, Liu YP, Zhu RY, Liu LX, Fang Y, Gao ZR, Gao DW (2018a) Magnetic resveratrol liposomes as a new theranostic platform for magnetic resonance imaging guided Parkinson's disease targeting therapy. ACS Sustain Chem Eng 6(12):17124–17133
Wang XH, Wang XY, Guo ZJ (2018b) Metal-involved theranostics: An emerging strategy for fighting Alzheimer's disease. Coord Chem Rev 362:72–84
Wang PZ, Zheng XY, Guo Q, Yang P, Pang XY, Qian K, Lu W, Zhang QZ, Jiang XG (2018c) Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. J Control Release 279:220–233
Wang W, Han Y, Fan Y, Wang Y (2019) Effects of gold nanospheres and nanocubes on amyloid-β peptide fibrillation. Langmuir 35(6):2334–2342
Warren JD, Rohrer JD, Rossor MN (2013) Frontotemporal dementia. BMJ 347:f4827
Wavikar PR, Vavia PR (2015) Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. J Liposome Res 25(2):141–149
Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY (2012) Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine 7:1599–1611
Weng M, Xie X, Liu C, Lim KL, Zhang CW, Li L (2018) The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson's disease. Parkinson’s Disease 2018:9163040
Whiteley CG (2014) Arginine metabolising enzymes as targets against Alzheimers' disease. Neurochem Int 67:23–31
Wilson B (2019) Drug targeting strategies into the brain for treating neurological diseases. J Neurosci Methods 311:133–146
Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh, B (2008a) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 1200:159–168
Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008b) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70(1):75–84
Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B (2009) Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. J Neurosci Methods 177(2):427–433
Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B (2010) Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 6(1):144–152
Wimo A, Jonsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Gulacsi L, Karpati K, Kenigsberg P, Valtonen H (2011) The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 26:825–832
Wischik CM, Novák M, Edwards PC, Klug A, Tichelaar W, Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4884–4888
Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64(7):686–700
Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, Bian ZX, Chen XY, Lu AP, Yang ZJ (2019) Review of current strategies for delivering Alzheimer's disease drugs across the blood-brain barrier. Int J Mol Sci 20(2):E381
Wu FG, Yang P, Zhang C, Li BL, Han XF, Song MH, Chen Z (2014) Molecular interactions between amantadine and model cell membranes. Langmuir 30(28):8491–8499
Xiang Y, Wu Q, Liang L, Wang XQ, Wang JC, Zhang X, Pu XP, Zhang Q (2012) Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model. J Drug Target 20(1):67–75
Xu MM, Zhou H, Liu YN, Sun J, Xie WJ, Zhao P, Liu J (2018) Ultrasound-excited protoporphyrin IX-modified multifunctional nanoparticles as a strong inhibitor of tau phosphorylation and β-amyloid aggregation. ACS Appl Mater Interfaces 10(39):32965–32980
Yan XJ, Xu LX, Bi CC, Duan DY, Chu LX, Yu X, Wu ZM, Wang AP, Sun KX (2018) Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. Int J Nanomedicine 13:273–281
Yang Z, Liu ZW, Allaker RP, Reip P, Oxford J, Ahmad Z, Ren G (2010a) A review of nanoparticle functionality and toxicity on the central nervous system. J R Soc Interface 7(4):S411–S422
Yang Z, Zhang YG, Yang YLA, Sun L, Han D, Li H, Wang C (2010b) Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine 6(3):427–441
Yang XX, Zheng RY, Cai YP, Liao ML, Yuan WE, Liu ZG (2012a) Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine 7:2077–2086
Yang XX, Chen YH, Hong XY, Wu N, Song L, Yuan WE, Liu ZG (2012b) Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. Drug Des Devel Ther 6:341–347
Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR (2013) Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 452(1–2):344–354
Yang X, Ji X, Shi C, Liu J, Wang H, Luan Y (2014a) Investigation on the ion pair amphiphiles and their in vitro release of amantadine drug based on PLGA-PEG-PLGA gel. J Nanopart Res 16(12):2780
Yang XF, He CE, Li J, Chen HB, Ma Q, Sui XJ, Tian SL, Ying M, Zhang Q, Luo YG, Zhuang ZX, Kiu JJ (2014b) Uptake of silica nanoparticles: neurotoxicity and Alzheimer-like pathology in human SK-N-SH and mouse neuro2a neuroblastoma cells. Toxicol Lett 229(1):240–249
Yang SY, Chiu MJ, Chen TF, Lin CH, Jeng JS, Tang SC, Lee YF, Yang CC, Liu BH, Chen HH, Wu CC (2017) Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci Rep 7:9304
Yang R, Zheng Y, Wang QJ, Zhao L (2018a) Curcumin-loaded chitosan–bovine serum albumin nanoparticles potentially enhanced Aβ 42 phagocytosis and modulated macrophage polarization in Alzheimer’s disease. Nanoscale Res Lett 13:330
Yang LC, Wang WJ, Chen JG, Wang N, Zheng GD (2018b) A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: inhibiting amyloid β aggregation and reactive oxygen species formation properties. J Biomed Mater Res A 106(12):3034–3041
Yang LC, Wang N, Zheng GD (2018c) Enhanced effect of combining chlorogenic acid on selenium nanoparticles in inhibiting amyloid β aggregation and reactive oxygen species formation in vitro. Nanoscale Res Lett 13:303
Yarjanli Z, Ghaedi K, Esmaeili A, Rahgozar S, Zarrabi A (2017) Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation. BMC Neurosci 18:51
Ye Y, Hui L, Lakpa KL, Xing YQ, Wollenzien H, Chen XS, Zhao J, Geiger JD (2019) Effects of silica nanoparticles on endolysosome function in primary cultured neurons. Can J Physiol Pharmacol 97(4):297–305
Yehia SA, El-Shafeey AH, El-Sayed I (2012) Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. J Pharm Pharmacol 64(10):1425–1437
Yi X, Wu YX, Tan GX, Yu P, Zhou L, Zhou ZN, Chen JQ, Wang ZG, Pang JS, Ning CY (2017) Palladium nanoparticles entrapped in a self-supporting nanoporous gold wire as sensitive dopamine biosensor. Sci Rep 7:7941
Yin TT, Yang LC, Liu YN, Zhou XB, Sun J, Liu J (2015) Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. Acta Biomater 25:172–183
Yin TT, Xie WJ, Sun J, Yang L, Liu J (2016) Penetratin peptide-functionalized gold nanostars: enhanced BBB permeability and NIR photothermal treatment of Alzheimer's disease using ultralow irradiance. ACS Appl Mater Interfaces 8(30):19291–19302
Yoo J, Lee E, Kim HY, Youn DH, Jung J, Kim H, Chang YJ, Lee W, Shin J, Baek S, Jang W, Jun W, Kim S, Hong J, Park HJ, Lengner CJ, Moh SH, Kwon Y, Kim J (2017) Electromagnetized gold nanoparticles mediate direct lineage reprogramming into induced dopamine neurons in vivo for Parkinson's disease therapy. Nat Nanotechnol 12(10):1006–1014
You LH, Wang J, Liu TQ, Zhang YL, Han XX, Wang T, Guo SS, Dong TY, Xu JC, Anderson GJ, Liu Q, Chang YZ, Lou X, Nie G (2018a) Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice. ACS Nano 12(5):4123–4139
You R, Ho YS, Hung CHL, Liu Y, Huang CX, Chan HN, Ho SL, Lui SY, Li HW, Chang RCC (2018b) Silica nanoparticles induce neurodegeneration-like changes in behavior, neuropathology, and affect synapse through MAPK activation. Part Fibre Toxicol 15:28
Yu YY, Wang P, Zhu XD, Peng QW, Zhou Y, Yin TX, Liang YX, Yin XX (2018) Combined determination of copper ions and β-amyloid peptide by a single ratiometric electrochemical biosensor. Analyst 143(1):323–331
Zaidi SA (2018) Development of molecular imprinted polymers based strategies for the determination of dopamine. Sensors Actuators B Chem 265:488–497
Zeinabad HA, Zarrabian A, Saboury AA, Alizadeh AM, Falahati M (2016) Interaction of single and multi wall carbon nanotubes with the biological systems: tau protein and PC12 cells as targets. Sci Rep 6:26508
Zhan QC, Shi XQ, Wang T, Hu JH, Zhou JH, Zhou L, Wei SH (2019) Design and synthesis of thymine modified phthalocyanine for Aβ protofibrils photodegradation and Aβ peptide aggregation inhibition. Talanta 191:27–38
Zhang C, Wan X, Zheng XY, Shao XY, Liu QF, Zhang QZ, Qian Y (2014a) Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 35(1):456–465
Zhang C, Chen J, Feng CC, Shao XY, Liu QF, Zhang QZ, Pang ZQ, Jiang XG (2014b) Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int J Pharm 461(1–2):192–202
Zhang NS, Yan F, Liang XL, Wu MX, Shen YY, Chen M, Xu YX, Zou GY, Jiang P, Tang CY, Zheng HR, Dai ZF (2018a) Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy. Theranostics 8(8):2264–2277
Zhang H, Dong XY, Liu FF, Zheng J, Sun Y (2018b) Ac-LVFFARK-NH2 conjugation to β-cyclodextrin exhibits significantly enhanced performance on inhibiting amyloid β-protein fibrillogenesis and cytotoxicity. Biophys Chem 235:40–47
Zhang HQ, Zhao YP, Yu M, Zhao ZQ, Liu PX, Cheng H, Ji Y, Jin Y, Sun B, Zhou JP, Ding Y (2019a) Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy. J Control Release 296:14–28
Zhang WJ, Christofferson AJ, Besford QA, Richardson JJ, Guo JL, Kempe K, Yarovsky J, Caruso F (2019b) Metal-dependent inhibition of amyloid fibril formation: synergistic effects of cobalt-tannic acid networks. Nanoscale 11(4):1921–1928
Zhang L, Zhao PG, Yue CP, Jin ZK, Liu Q, Du XB, He QJ (2019c) Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer's disease. Biomaterials 197:393–404
Zhao GF, Dong XY, Sun Y (2019) Self-assembled curcumin-poly(carboxybetaine methacrylate) conjugates: potent nano-inhibitors against amyloid β-protein fibrillogenesis and cytotoxicity. Langmuir 35(5):1846–1857
Zheng XY, Shao XY, Zhang C, Tan YZ, Liu QF, Wan X, Zhang QZ, Xu SM, Jiang XG (2015) Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer's disease. Pharm Res 32(12):3837–3849
Zhou YZ, Alany RG, Chuang V, Wen JY (2013) Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design. Drug Dev Ind Pharm 39(2):321–330
Zhou WH, Wang HH, Li WT, Guo XC, Kou DX, Zhou ZJ, Meng YN, Tian QW, Wu SX (2018) Gold nanoparticles sensitized ZnO nanorods arrays for dopamine electrochemical sensing. J Electrochem Soc 165(12):G3001–G3007
Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417(6884):74–78
Acknowledgements
This study was supported by the Slovak Research and Development Agency (project APVV-14-0547) and by the Ministry of Education of the Czech Republic (LO1305).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Additional information
This chapter is sincerely dedicated to the memory of Professor Karol Matulay (1906–1998), nestor of Slovak psychiatry and neurology.
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jampílek, J., Kráľová, K., Novák, P., Novák, M. (2019). Nanobiotechnology in Neurodegenerative Diseases. In: Rai, M., Yadav, A. (eds) Nanobiotechnology in Neurodegenerative Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-30930-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-30930-5_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30929-9
Online ISBN: 978-3-030-30930-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)